Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Next to HbA1c, body weight is regarded as an important surrogate end-point in trials
investigating glucose-lowering agents. An increase in weight could contribute to worsening
insulin resistance. Differences in weight after starting glucose lowering agents have been
described in many randomized controlled trials (RCTs).
With this prospective observational study, weight trajectories after receiving add-on therapy
next to metformin are evaluated in primary care patients with good glycaemic control.